Allogene Therapeutics (ALLO) Stock Price, News & Analysis

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ALLO shares.
View ALLO analyst ratings or view top-rated stocks.

7 analysts have issued 1-year price targets for Allogene Therapeutics' stock. Their ALLO share price targets range from $7.00 to $28.00. On average, they anticipate the company's stock price to reach $12.94 in the next twelve months. This suggests a possible upside of 272.8% from the stock's current price.
View analysts price targets for ALLO or view top-rated stocks among Wall Street analysts.

Allogene Therapeutics' stock was trading at $3.21 at the beginning of the year. Since then, ALLO stock has increased by 8.1% and is now trading at $3.47.
View the best growth stocks for 2024 here.

Allogene Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 30,620,000 shares, an increase of 10.3% from the March 15th total of 27,750,000 shares. Based on an average daily trading volume, of 2,610,000 shares, the days-to-cover ratio is presently 11.7 days. Approximately 29.3% of the shares of the stock are sold short.
View Allogene Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our ALLO earnings forecast.

Allogene Therapeutics, Inc. (NASDAQ:ALLO) released its earnings results on Thursday, March, 14th. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.04. The company earned $0.02 million during the quarter, compared to analysts' expectations of $0.05 million. Allogene Therapeutics had a negative net margin of 202,366.25% and a negative trailing twelve-month return on equity of 53.76%.

ETFs with the largest weight of Allogene Therapeutics (NASDAQ:ALLO) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), Direxion Moonshot Innovators ETF (MOON), Range Cancer Therapeutics ETF (CNCR), Virtus LifeSci Biotech Clinical Trials ETF (BBC), iShares Genomics Immunology and Healthcare ETF (IDNA) and Global X Genomics & Biotechnology ETF (GNOM).Horizon Kinetics Medical ETF (MEDX).

2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com. David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP).

Allogene Therapeutics (ALLO) raised $272 million in an initial public offering (IPO) on Thursday, October 11th 2018. The company issued 16,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO.

Allogene Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.09%) and Bourgeon Capital Management LLC (0.03%). Insiders that own company stock include Alison Moore, Arie Belldegrun, David D Chang, Deborah M Messemer, Eric Thomas Schmidt, Geoffrey M Parker, Owen N Witte, Owen N Witte, Rafael Amado, Stephen Mayo and Veer Bhavnagri.
View institutional ownership trends.

Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.